Turmeric and its active compound, curcumin, has gained popularity as an herbal supplement due to its anti-inflammatory properties. However, the lack of standardized regulation for herbal supplements raises concerns about potential side effects and toxicity. This case report presents a 53-year-old woman with Behçet disease who developed biopsy-proven drug-induced liver injury (DILI) after initiating a turmeric supplement, with resolution of laboratory abnormalities after a positive supplement de-challenge. This case highlights the importance of noting herbal supplementation during medication reconciliation and underscores the need for rigorous regulatory oversight to ensure the safety of such products.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864403 | PMC |
| http://dx.doi.org/10.56305/001c.122729 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Liver fibrosis is a global health problem. IL-17A has proven profibrogenic properties in liver disease making it an interesting therapeutic target. IL-17A is regulated by RORγt and produced by Th17 CD4+ and γδ-T cells.
View Article and Find Full Text PDFThe Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients.
Drug Saf
March 2025
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Introduction: Most epidemiological studies have found antibiotics to be the most common cause of drug-induced liver injury (DILI). It is unclear what the risk of DILI is associated with different antibiotics.
Objective: The aim of the study was to assess the frequency of DILI due to the most commonly used antibiotics among inpatients, in a population-based setting.
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature.
Cancer Chemother Pharmacol
March 2025
Medical Oncology, Department of Clinical and Molecular Sciences, University Politecnica delle Marche, Ancona, 60126, Italy.
In recent years, assessing dihydropyrimidine dehydrogenase (DPD) activity has become crucial for cancer patients undergoing 5-fluorouracil (5FU)-based chemotherapy due to the life-threatening toxicity associated with reduced DPD function. The methods for evaluating DPD activity have evolved, with the analysis of DPYD polymorphisms in blood samples becoming the preferred approach. As the indications for liver transplantation are increasing-particularly due to a rise in cases of cholangiocarcinoma (CCA) and non-resectable colorectal liver metastasis-more cancer patients with a history of liver transplantation may experience disease relapse.
View Article and Find Full Text PDFContinuous Kidney Replacement Therapies: Core Curriculum 2025.
Am J Kidney Dis
March 2025
Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:
Critically ill patients that require kidney replacement therapy (KRT) are among the most ill and complex patients routinely encountered in the intensive care unit (ICU). Continuous KRT (CKRT) is used across many ICUs as the therapy of choice for hemodynamically unstable patients with kidney failure. Though existing trials have not shown superior survival or kidney recovery with CKRT relative to intermittent KRT, CKRT has largely become the standard of care in developed nations for the treatment of acute kidney injury (AKI) in patients with shock, acute brain injury, acute liver failure, and other forms of critical illness.
View Article and Find Full Text PDFEnhanced FGF21 Delivery via Neutrophil-Membrane-Coated Nanoparticles Improves Therapeutic Efficacy for Myocardial Ischemia-Reperfusion Injury.
Nanomaterials (Basel)
February 2025
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Acute myocardial infarction, a leading cause of death globally, is often associated with cardiometabolic disorders such as atherosclerosis and metabolic syndrome. Metabolic treatment of these disorders can improve cardiac outcomes, as exemplified by the GLP-1 agonist semaglutide. Fibroblast growth factor 21 (FGF21), a novel metabolic regulator, plays pivotal roles in lipid mobilization and energy conversion, reducing lipotoxicity, inflammation, mitochondrial health, and subsequent tissue damage in organs such as the liver, pancreas, and heart.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!